{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-023401","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2022-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.223898+00:00","generated_at":"2026-06-27T13:46:49.782678+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amgen amends Aimovig collaboration with Novartis, ends US royalties and cost-sharing","bullets":["Novartis gets sole commercialization rights for Aimovig outside US and Japan; Amgen ends royalty payments on US sales.","U.S. Collaboration Agreement terminated Jan 31, 2022; parties no longer share US commercialization costs.","Amgen's share of Franchise Product 1 (Aimovig) development costs capped at $[***] aggregate; thereafter split 50/50.","Litigation between the parties resolved concurrently with these amendments.","Novartis to fund US Medical Affairs activities until a defined completion date."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-023401","json":"https://secwatch.observer/filing/0001193125-22-023401.json","markdown":"https://secwatch.observer/filing/0001193125-22-023401.md","text":"https://secwatch.observer/filing/0001193125-22-023401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000119312522023401/0001193125-22-023401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000119312522023401/d275986d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T13:46:49.782678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}